论文部分内容阅读
目的观察布地奈德雾化吸入对肺炎支原体肺炎患儿临床症状、肺功能及体液免疫功能的影响。方法收集医院治疗的肺炎支原体患儿82例,随机分为观察组和对照组,每组41例。对照组给予阿奇霉素常规治疗,观察组在对照组基础上给予布地奈德雾化吸入治疗,治疗2周后,比较2组症状改善情况、肺功能变化[肺活量(FVC)、第一秒呼气容积(FEV1)]及体液免疫功能变化(血清免疫球蛋白水平,指标包括IgA、IgM、IgG等)。结果观察组治疗总有效率为75.12%,高于对照组的78.05%(P<0.05);观察组治疗后FVC、FEV1水平均显著优于对照组(P<0.01);观察组治疗后IgA、IgM、IgG水平均显著优于对照组(P<0.01)。结论肺炎支原体患儿联合采用布地奈德雾化吸入治疗的效果显著,改善患儿肺功能及免疫功能,值得推广应用。
Objective To observe the effects of inhaled budesonide on clinical symptoms, pulmonary function and humoral immune function in children with Mycoplasma pneumoniae pneumonia. Methods Eighty-two children with Mycoplasma pneumoniae were collected and randomly divided into observation group and control group, 41 cases in each group. The control group was treated with azithromycin routinely. The observation group was treated with inhaled budesonide inhalation on the basis of the control group. After 2 weeks of treatment, the symptoms of the two groups were compared, the changes of lung function [FVC, the first second expiratory volume (FEV1)] and changes in humoral immune function (serum immunoglobulin levels, including IgA, IgM, IgG, etc.). Results The total effective rate of observation group was 75.12%, which was higher than that of control group (78.05%, P <0.05). The levels of FVC and FEV1 in observation group were significantly better than those in control group (P <0.01) IgM, IgG levels were significantly better than the control group (P <0.01). Conclusion Mycoplasma pneumoniae combined with budesonide inhalation therapy has significant effect, to improve children’s lung function and immune function, it is worth promoting the application.